AI Article Synopsis
- An efficient method for creating a prodrug that combines 5-fluorouracil with cephalosporin is presented, aimed at treating colorectal and other cancers through targeted therapies.
- This prodrug remains stable in water until it is activated by a specific enzyme called beta-lactamase (betaL).
- The study measured the kinetic properties of the prodrug when exposed to a specific strain of bacteria, providing valuable data for future testing against cancer cells in lab and animal studies.
Article Abstract
An efficient synthesis of a 5-fluorouracil-cephalosporin prodrug is described for use against colorectal and other cancers in antibody and gene-directed therapies. The compound shows stability in aqueous media until specifically activated by beta-lactamase (betaL). The kinetic parameters of the 5-fluorouracil-cephalosporin conjugate were determined in the presence of Enterobacter cloacae P99 betaL (ECl betaL) revealing a K(m)=95.4 microM and V(max)=3.21 microMol min(-1) mg(-1). The data compare favorably to related systems that have been reported and enable testing of this prodrug against cancer cell lines in vitro and in vivo.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838426 | PMC |
| http://dx.doi.org/10.1016/j.bmcl.2008.12.057 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!